Pfizer acquired NextWave Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system disorders. The agreement includes Quillivant XR (methylphenidate HCl), the first once-daily liquid ADHD treatment in the United States. Pfizer launched Quillivant XR in the U.S. in January 2013—providing patients and their caregivers a new treatment option for the disorder.
Pfizer and the Cardiovascular Epidemiology Unit at the University of Cambridge in the U.K. have established a collaboration that strives to develop new medicines for cardiovascular disease. Pfizer brings a strong precision medicine focus to the collaboration, which has Pfizer scientists and University of Cambridge researchers working side by side. This collaboration with some of Europe's top experts in population health sciences furthers Pfizer’s strategy to tap into leading scientific minds and resources in academia.
Pfizer and France’s Institut du Cerveau et de la Moelle Épinière (ICM Brain and Spine Institute) are embarking on a three-year scientific collaboration to investigate the fundamental mechanisms of certain neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases. Based in Paris, ICM is a major scientific center, composed of more than 500 researchers and physicians focused on fundamental and translational neuroscience research, with a strong emphasis on industry partnerships.
Pfizer and Hisun, a leading China-based pharmaceutical company, have launched Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture to provide high quality, affordable branded generic medicines for patients in China and other global markets. Hisun-Pfizer is expected to develop, manufacture and commercialize a range of off-patent pharmaceutical products.
Pfizer and Mylan, the world’s third-largest generics and specialty pharmaceuticals company, have forged an exclusive strategic collaboration to drive growth of the generics business in Japan, the second-largest pharmaceutical market in the world. The collaboration builds on Pfizer’s already-strong commercial presence and Mylan’s reputation for global quality, manufacturing and supply chain reliability for its generic medicines.
Regulators in Europe have approved the use of docetaxel, a sterile injectable developed by Pfizer Global Supply in Perth, Australia, for the treatment of breast, ovarian, prostate and non-small cell lung cancer. Docetaxel features a single-vial preparation manufactured in plastic Cytosafe vials, which offer significant safety benefits over a competing innovator’s two-stage injection system. Docetaxel is also stable at room temperature and has a commercially viable shelf life of at least 24 months.
